Compare GRF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | PRPO |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 44.4M |
| IPO Year | N/A | 2000 |
| Metric | GRF | PRPO |
|---|---|---|
| Price | $10.20 | $30.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.9K | ★ 14.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $9.50 | $6.29 |
| 52 Week High | $11.85 | $33.63 |
| Indicator | GRF | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 51.58 |
| Support Level | $9.60 | $22.96 |
| Resistance Level | $10.61 | $29.66 |
| Average True Range (ATR) | 0.16 | 2.41 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 63.76 | 46.51 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.